VTGNVistaGen Therapeutics, Inc.

0.2440USD-0.04%Mkt Cap: 10.83M $P/E:

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline inclu…

HeadlineSourceTime
Older
SRX Global Acquires Stake in Vistagen Therapeutics

SRX Global (AMEX:SRXH) disclosed an investment in Vistagen Therapeutics (NASDAQ:VTGN) and said it intends to engage with the company’s leadership and board on potential shareholder value initiatives. Key Investor TakeawaysSRX Global (AMEX:SRXH) acquired a stake in Vistagen Therapeutics (NASDAQ:VTGN).

InvestorsHub
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is one of the best psychedelic stocks on our list. TheFly reported on June 30 that VTGN announced topline findings from the PALISADE-4 Phase 3 trial evaluating intranasal fasedienol for the acute treatment of social anxiety […]

IInsider Monkey
Zacks